CS-138turnaround
Teva Pharmaceutical Industries Ltd. (listed in New York and Tel Aviv, headquartered in Israel)
Two-stage recovery after the Actavis Generics acquisition: the December 2017 restructuring plan (14,000 roles, US$3bn cost reduction, dividend suspension, deleveraging) and the May 2023 'Pivot to Growth' strategy (2017-2025)
- Region
- Middle East, North America
- Country
- Israel, United States
- Industry
- Pharmaceuticals and Life Sciences (Chemicals and Process Manufacturing)
- Functions
- Strategy, Corporate Development & Transformation Office, Finance & FP&A, Treasury & Working Capital, HR & Workforce, Manufacturing & Production, Product, R&D & Innovation
- Topics
- Revenue growth has stalled; Margins are eroding despite revenue; Cash is trapped and liquidity is tightening; M&A integration or corporate complexity is destroying value; Workforce costs and capacity no longer match demand; Regulatory complexity is overwhelming controls
- Starting situation
- Stalled or failing (turnaround)
- Period
- 2017–2025
- Last verified
- 4 November 2026
Executive summary
Teva, an Israel-based producer mainly of generic medicines, bought Allergan's generics business for US$40.5bn in 2016 shortly before US generic prices came under heavier pressure, and its main branded drug, Copaxone, met generic competition [C01, C07]. By late 2017 its debt was US$34.7bn, its shares had hit a 17-year low, and it reported a 2017 GAAP loss of US$16.3bn after a US$17.1bn goodwill write-down [C02, C08].
A new chief executive, Kåre Schultz, announced within six weeks a plan to cut about 14,000 jobs and US$3bn of costs by 2019, suspend the dividend and close plants and offices; Teva met the cost target and cut net debt by more than US$9bn [C03, C04, C11]. A second chief executive, Richard Francis, launched 'Pivot to Growth' in 2023 to shift the mix toward innovative medicines [C13, C14].
Revenue grew in 2023, 2024 and 2025, total debt fell to US$16.8bn and Teva reported 2025 GAAP net income of US$1.41bn [C17, C19]. The lesson for a CEO: in a debt-driven crisis, a fast, quantified cost and cash plan buys time, but only a second, explicit growth strategy turns the time into a recovery.
Outcome: turnaround
The company started in documented distress (losses, near-insolvency, rescue) and then reported a sustained return to profit or growth.
Basis of the outcome
Teva started in documented distress: a 2017 GAAP net loss of US$16.3bn after a US$17.1bn goodwill impairment, debt of US$34.7bn, loss of its investment-grade rating and a suspended dividend (S03, S05, S06). It met its US$3bn cost-reduction target in 2019 and cut net debt by more than US$9bn (S07, S08); revenue grew in 2023, 2024 and 2025, total debt fell to US$16.8bn, and 2025 GAAP net income was US$1.41bn against a loss in 2024 (S13, S15). A documented start in distress followed by three years of growth and a return to GAAP profit meets the turnaround criterion.
Key figures
| Phase | Figure | Value | When | Verification |
|---|---|---|---|---|
| Before | GAAP net loss | US$16.3bn | 2017 | company_reported |
| Before | Goodwill impairment | US$17.1bn | 2017 | company_reported |
| Before | Debt | US$34.7bn | Sep 2017 | multiple_independent |
| During | Positions cut | about 14,000 | Dec 2017 | multiple_independent |
| During | Cost reduction target | US$3bn by end-2019 | Dec 2017 | multiple_independent |
| During | Net debt reduction | more than US$9bn | 2019 | press_reported |
| After | Revenue | US$17.26bn | 2025 | regulatory_filing_unaudited |
| After | GAAP net income | US$1.41bn | 2025 | regulatory_filing_unaudited |
| After | Total debt | US$16.8bn | 2025 | regulatory_filing_unaudited |
| After | Free cash flow | US$2.40bn | 2025 | regulatory_filing_unaudited |
- company_reported
- A company statement, press release or investor presentation that no one has independently checked.
- multiple_independent
- Two or more independent sources agree.
- press_reported
- A journalist's own reporting.
- regulatory_filing_unaudited
- Text in an 8-K, 6-K or 10-Q, which is filed with a regulator but not audited.
Practices this case bears on
- SupportsName one accountable sponsor, keep sponsorship stable, and treat a leadership change as a re-baselining event BP-003
- SupportsMake a few quantified, dated commitments, publish them, and report against them, including the misses BP-004
- SupportsIn distress, stabilise cash and cost first, repair the core next, and invest for growth only then BP-005
- SupportsAfter a control or conduct failure, fix governance, leadership and incentives before strategy, and keep individual accountability proportionate and separate BP-025
- SupportsRenew the leadership team quickly, choosing leaders from where the business is going BP-029
- SupportsAnnounce only targets the evidence supports, build synergy estimates from shared data, and re-base them openly BP-033
- SupportsSeparate the programme's own effect from tailwinds, shocks and one-off gains before claiming credit BP-035
- SupportsSet a walk-away price from stand-alone value plus provable synergies, and re-test the deal when it changes BP-039
- SupportsFinance and size big bets so the company survives a downturn in the first years BP-040
- SupportsSecure the cash runway before you need it, and measure liquidity at its worst point BP-044
- SupportsPair cost reduction with a growth strategy, and protect the investments that define the future while cutting BP-046
- SupportsPlan workforce change as a funded people programme: delayer first, share the upside, and redeploy where you can BP-049
- SupportsRun the old and new models side by side, funded by the old, and tell investors which numbers will replace the old ones BP-055
- SupportsDecide what litigation or a dispute is for, and settle against its full cost and duration BP-067
- SupportsProtect operations, customers and staff explicitly from the first day of a restructuring BP-077
Sources
- S01 Teva Pharmaceuticals to slash 14,000 jobs and suspend its dividend · not stated, CNBC, 2017-12-14 · accessed 2026-11-04
- S02 Teva's New CEO Is Cutting 25% of Jobs to Rescue the Ailing Drugmaker · Bloomberg, Fortune (Bloomberg), 2017-12-14 · accessed 2026-11-04
- S03 Teva to cut 14,000 jobs · not stated, CNN Money, 2017-12-14 · accessed 2026-11-04
- S04 Teva Pharmaceutical Industries Ltd. Form 10-K for fiscal year 2017 · Teva Pharmaceutical Industries Ltd., U.S. Securities and Exchange Commission (EDGAR), 2018-02 · accessed 2026-11-04
- S05 Teva Reports 2017 Full Year and Fourth Quarter Financial Results · Teva Pharmaceutical Industries Ltd., BioSpace (repost of Business Wire release), 2018-02-08 · accessed 2026-11-04
- S06 Teva chief reports 'strong progress' in restructuring plan · Josef Federman, The Times of Israel (Associated Press), 2018-02-08 · accessed 2026-11-04
- S07 Teva Reports Fourth Quarter and Full Year 2019 Financial Results · Teva Pharmaceutical Industries Ltd., BioSpace (repost of Business Wire release), 2020-02-12 · accessed 2026-11-04
- S08 After turbulent years, Teva CEO Schultz forecasts stability · Eytan Halon, The Jerusalem Post, 2020-02-19 · accessed 2026-11-04
- S09 Teva reaches proposed $4.25bn agreement to settle US opioid lawsuits · Emily Kimber, PMLive (PharmaFile), 2022-07-28 · accessed 2026-11-04
- S10 Teva Launches New 'Pivot to Growth' Strategy · Teva Pharmaceutical Industries Ltd., BioSpace (repost of Business Wire release), 2023-05-18 · accessed 2026-11-04
- S11 Teva targets growth through innovation · Shiri Habib-Valdhorn, Globes, 2023-05-18 · accessed 2026-11-04
- S12 Teva to pay $225 million in fines and divest generic drug to resolve price-fixing charges · not stated, CNBC, 2023-08-21 · accessed 2026-11-04
- S13 Teva Reports Growth in Fourth Quarter and Full Year 2023 (Exhibit 99.1 to Form 8-K) · Teva Pharmaceutical Industries Ltd., U.S. Securities and Exchange Commission (EDGAR), 2024-01-31 · accessed 2026-11-04
- S14 Pivot to Growth: The Acceleration Phase · Teva Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., 2026-02-17 · accessed 2026-11-04
- S15 Form 8-K with Exhibit 99.1: Teva Reports 2025 Full Year and Fourth Quarter Financial Results · Teva Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. (investor relations copy of SEC filing), 2026-01-28 · accessed 2026-11-04
- S16 Teva Reports Fourth Quarter and Full Year 2020 Financial Results (Exhibit 99.1 to Form 8-K) · Teva Pharmaceutical Industries Ltd., U.S. Securities and Exchange Commission (EDGAR), 2021-02-10 · accessed 2026-11-04
Researched and fact-checked knowledgebase · Knowledgebase built 5 November 2026 · Last verified 4 November 2026
Practices, their evidence grades and case summaries are public. Full case studies are available in AXIOM to subscribers and AXIOM Discover participants.

